Endonovo Therapeutics (ENDV) Free Cash Flow (2018 - 2023)
Endonovo Therapeutics has reported Free Cash Flow over the past 12 years, most recently at -$65367.0 for Q3 2023.
- Quarterly results put Free Cash Flow at -$65367.0 for Q3 2023, up 47.23% from a year ago — trailing twelve months through Sep 2023 was -$629904.0 (up 25.42% YoY), and the annual figure for FY2022 was -$678838.0, up 31.19%.
- Free Cash Flow for Q3 2023 was -$65367.0 at Endonovo Therapeutics, up from -$138996.0 in the prior quarter.
- Over the last five years, Free Cash Flow for ENDV hit a ceiling of -$65367.0 in Q3 2023 and a floor of -$1.0 million in Q3 2019.
- Median Free Cash Flow over the past 5 years was -$200000.0 (2023), compared with a mean of -$281742.4.
- Biggest five-year swings in Free Cash Flow: skyrocketed 90.5% in 2020 and later crashed 102.9% in 2021.
- Endonovo Therapeutics' Free Cash Flow stood at -$308381.0 in 2019, then soared by 37.46% to -$192856.0 in 2020, then crashed by 102.9% to -$391296.0 in 2021, then soared by 42.36% to -$225541.0 in 2022, then soared by 71.02% to -$65367.0 in 2023.
- The last three reported values for Free Cash Flow were -$65367.0 (Q3 2023), -$138996.0 (Q2 2023), and -$200000.0 (Q1 2023) per Business Quant data.